CD274 and neoplasm: PD-1 and PD-L1 are major targets for therapeutic intervention, particularly in oncology, where several antagonistic PD-1/PD-L1 antibodies that block PD-1–mediated T cell inhibition have demonstrated efficacy in a variety of tumour types and are now approved anticancer therapies (2, 3, 8).